Xyphos Biosciences, Inc., a wholly owned subsidiary of Astellas Pharma Inc., and Poseida Therapeutics Inc., have entered into a research collaboration and license agreement to develop novel convertibleCAR programs by combining the cell therapy platforms of each company.   Poseida is advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. In oncology, its pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and l...